Edition:
United Kingdom

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.49USD
19 Oct 2018
Change (% chg)

$-0.15 (-5.68%)
Prev Close
$2.64
Open
$2.63
Day's High
$2.63
Day's Low
$2.46
Volume
32,954
Avg. Vol
35,206
52-wk High
$3.95
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Celsion Corp Files For Mixed Shelf Of Up To $75 Million
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Celsion Corp ::CELSION CORP FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING.  Full Article

Celsion Strengthens Its Balance Sheet With The Approval Of Its Application To Sell Net Operating Losses For Up To $10 Million In Non-Dilutive Funding
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Celsion Corp ::PRESS RELEASE - CELSION STRENGTHENS ITS BALANCE SHEET WITH THE APPROVAL OF ITS APPLICATION TO SELL NET OPERATING LOSSES FOR UP TO $10 MILLION IN NON-DILUTIVE FUNDING.CELSION - CO ANTICIPATES TO TRANSFER CREDIT & RECEIVE UPTO $10 MILLION NET CASH PROCEEDS PRIOR TO 2018-END.  Full Article

Celsion Corp Announces Strategic Loan Facility
Thursday, 28 Jun 2018 

June 28 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES STRATEGIC LOAN FACILITY.CELSION CORP - ON JUNE 27, ENTERED INTO A $10 MILLION LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION.CELSION CORP - WILL USE FUNDING PROVIDED UNDER AGREEMENT FOR WORKING CAPITAL AND ADVANCEMENT OF ITS PRODUCT PIPELINE.  Full Article

Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Celsion Corp ::CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER.CELSION CORP - EXPECTS TO INITIATE ENROLLMENT OF PHASE I PORTION OF OVATION II STUDY IN FIRST HALF OF 2018.CELSION CORP - COMPANY EXPECTS TO HAVE 25% OF OVATION II STUDY ENROLLED BY END OF 2018.  Full Article

Celsion reports Q3 loss of $0.70/shr
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Celsion Corp :Celsion Corporation reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.70.  Full Article

CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK.‍PRICING OF OFFERING OF 2.64 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 1.32 MILLION SHARES OF COMMON STOCK AT $2.50/SHARE, RELATED WARRANTS​.  Full Article

Celsion Corp Q2 loss per share $0.79
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Celsion Corp :Celsion corporation reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.79.Celsion corp - ‍expects to complete enrollment of optima study by mid - 2018.​.  Full Article

Celsion cancels registered direct offering
Thursday, 22 Jun 2017 

June 22 (Reuters) - Celsion Corp ::Celsion Corporation announces cancellation of registered direct offering.Company noted it did not possess ability to register a sufficient number of shares pursuant to form S-3 until July 1, 2017.Company has entered into an agreement with each of investors to terminate offering.Cancelled registered direct offering of common stock announced Monday, June 19.  Full Article

Celsion Corp announces positive DSMB review of Phase 1B ovation study in ovarian cancer
Thursday, 1 Dec 2016 

Celsion Corp : Celsion Corporation announces positive DSMB review of Phase 1B ovation study in ovarian cancer . Celsion - study to continue as planned, co to proceed with completing dosing in fourth and final patient cohort, which is currently enrolling patients. .Celsion Corp - expect to report final data from ovation study C in Q1 of 2017.  Full Article